C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • Patent number: 10513494
    Abstract: Methods of treatment useful in the inducement or maintenance of anesthesia in a subject are provided. The methods comprise administering to a subject in need of anesthesia a compound disclosed herein. Also provided are novel compounds having anesthetic effects, pharmaceutical compositions comprising the compounds, and packaged pharmaceuticals. Computer modeling of the compounds demonstrates favorable interactions with the GABA receptor type A. In addition, the compounds display reversible anesthetic effects in an animal model, with dose-response curves similar to those of known general anesthetics. GABA receptor-mediated effects are also demonstrated in a hippocampal brain slice preparation.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 24, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States Government as represented by the Department Of Veterans Affairs
    Inventors: Edward John Bertaccini, Margaret Frances Davies
  • Patent number: 10500187
    Abstract: Plant phenols, in particular, plant phenolic acids, like rosmarinic acid, ellagic acid, and chlorogenic acid, are used in preventing or reducing transepidermal water loss (TEWL) and associated disorders and diseases.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: December 10, 2019
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Carine Blanchard, Marjorie Guitard, Sebastien Holvoet
  • Patent number: 10493059
    Abstract: The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: December 3, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventor: Valerie Morisset
  • Patent number: 10441568
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 15, 2019
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara Goldstein, Amram Samuni, Neville Berkman
  • Patent number: 10414750
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 17, 2019
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10357470
    Abstract: Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 23, 2019
    Assignee: KANE BIOTECH INC.
    Inventors: Purushottam V. Gawande, Karen Lovetri, Nandadeva Yakandawala, Gordon Froehlich, Srinivasa Madhyastha
  • Patent number: 10329252
    Abstract: The present invention provides a compound represented by General Formula (I). The compound according to the present invention prevents the liquid crystal composition from being deteriorated due to light, has high compatibility with the liquid crystal composition, and does not impair the storage stability of the liquid crystal composition, thus the compound is useful as a constituent member of a liquid crystal composition. Since the liquid crystal composition and the liquid crystal display element containing the compound of the present invention exhibit UV resistance and have a high VHR, it is possible to obtain a liquid crystal display element with excellent display quality in which display defects such as burn-in and display unevenness do not occur or are suppressed.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: June 25, 2019
    Assignee: DIC CORPORATION
    Inventors: Yoshio Aoki, Ayaki Hosono
  • Patent number: 10314803
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: June 11, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Mehar Manku
  • Patent number: 10308597
    Abstract: This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 4, 2019
    Assignee: Rgenix, Inc.
    Inventors: Eduardo J. Martinez, Sohail F. Tavazoie
  • Patent number: 10159648
    Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: December 25, 2018
    Assignee: AgeneBio, Inc.
    Inventors: Michela Gallagher, Sharon Rosenzweig-Lipson, Elsie Melsopp, Jack Lawrence James
  • Patent number: 10113171
    Abstract: An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A vector comprising a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 and a pharmaceutical composition comprising an active agent capable of reducing quinone reductase 2 activity or said vector are provided as well.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: October 30, 2018
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Patent number: 10100003
    Abstract: Disclosed are salts, such as nitrates, of acetyl-L-carnitine and propionyl-L-carnitine and methods of making the compounds.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 16, 2018
    Assignee: Thermolife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10100010
    Abstract: The present invention provides a 4-methoxy pyrrole derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof according to the present invention have not only excellent proton pump inhibitory activity, gastric damage-inhibiting activity and defensive factor-enhancing effects, but also excellent eradication activity against H. pylori. Therefore, the 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof can be effectively used for the prevention and treatment of gastrointestinal damage due to gastrointestinal tract ulcer, gastritis, reflux esophagitis or H. pylori.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 16, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Chun Ho Lee, Seung Chul Lee, Yeon Im Lee, Deok Ki Eom, Mi Ryeong Han, Eun Ji Koh
  • Patent number: 10071962
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 11, 2018
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Patent number: 10052281
    Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 21, 2018
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Koichi Kitamura, Maho Kondo, Kiyoshi Shimoyama, Toru Kurosawa
  • Patent number: 10016393
    Abstract: The present disclosure relates to: (a) methods of using stabilized pharmaceutical dosage forms comprising atrasentan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent to treat type 2 diabetes, microalbuminuria or macroalbuminuria; and (b) methods for the preparation of such pharmaceutical dosage forms.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 10, 2018
    Assignee: AbbVie Inc.
    Inventors: Ye Huang, Andrew K. Koski, Katherine E. Peterson
  • Patent number: 10015980
    Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 10, 2018
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Valter D. Longo, Chia-Wei Cheng, Sebastian Brandhorst, Min Wei
  • Patent number: 9938238
    Abstract: Provided herein are methods and compositions for controlling auxin responses in plants.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: April 10, 2018
    Assignee: The Regents of the University of California
    Inventor: Paul Brian Larsen
  • Patent number: 9839668
    Abstract: The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: December 12, 2017
    Assignee: ATTOQUANT DIAGNOSTICS GMBH
    Inventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner
  • Patent number: 9820966
    Abstract: The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 21, 2017
    Assignee: CUMBERLAND PHARMACEUTICALS
    Inventors: Leo Pavliv, Andrew Vila
  • Patent number: 9782336
    Abstract: The present invention provides a composition containing (A) and (B), which shows a decreased peculiar odor of acylproline and a salt thereof, has a moist feeling and is superior in the stability: (A) acylproline represented by the formula (1) or a salt thereof (wherein an acyl group represented by R1—CO— is an acyl group induced from saturated or unsaturated fatty acid having 3-23 carbon atoms) (B) a zinc salt of pyrrolidone carboxylate.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 10, 2017
    Assignee: AJINOMOTO CO., INC.
    Inventors: Nana Haraya, Eiko Oshimura
  • Patent number: 9682933
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: June 20, 2017
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Luping Yan, Raymond J. Andersen, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Patent number: 9676713
    Abstract: The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (I) [wherein R1 represents a methyl group or a trifluoromethyl group, R2 represents a hydrogen atom or a C1-C3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: June 13, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Takahiro Okachi, Michiaki Kawahara, Hiroshi Nagasawa, Noritada Sato, Takashi Takita, Gen Hasegawa
  • Patent number: 9616046
    Abstract: The present invention relates to a hepatocyte-proliferating agent comprising pyroglutamic acid, aspartic acid, and glutamic acid as active ingredients, in particular, a hepatocyte-proliferating agent capable of selectively proliferating normal hepatocytes without proliferating cancer cells.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: April 11, 2017
    Assignee: JAPAN BIO PRODUCTS Co., Ltd.
    Inventors: Shinjiro Inoue, Eiichi Hirano, Tetsuo Morinaga
  • Patent number: 9612242
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: April 4, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9573883
    Abstract: Disclosed are salts, such as nitrates, of acetyl-L-carnitine and propionyl-L-carnitine and methods of making the compounds.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: February 21, 2017
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • Patent number: 9487505
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 8, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • Patent number: 9422335
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 23, 2016
    Assignee: UTI Limited Partnership
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Patent number: 9387234
    Abstract: A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1).
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 12, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Silviu Itescu
  • Patent number: 9346814
    Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 24, 2016
    Assignees: Universiteit Antwerp, Fox Chase Cancer Center
    Inventors: Koen Jansen, Ingrid De Meester, Leen Heirbaut, Jonathan D Cheng, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
  • Patent number: 9340500
    Abstract: A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I), wherein R1a is substituted or unsubstituted alkyl or the like; R1b is hydrogen or substituted or unsubstituted alkyl; R1c is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted nonaromatic heterocyclic group or the like; -L- is —C(=0)—NR2? or the like; X is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 17, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Akira Yukimasa
  • Patent number: 9226965
    Abstract: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: January 5, 2016
    Assignee: U.S. DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Wesley W. Brooks, Oscar H.L. Bing
  • Patent number: 9198942
    Abstract: A bioactive compound obtained from A. cinnamomea mycelium is prepared. The A. cinnamomea mycelium is solid-state cultivated. The bioactive compound is 2,3,6-trimethoxy-4-methylphenol and is called Leader 1. Leader 1 effectively suppresses movement, migration and invasion of lung cancer cells. Leader 1 achieves the effect of anti-metastasis and shows excellent resistance to physiological activity and mechanism on cancer metastasis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 1, 2015
    Assignee: TAIWAN LEADER BIOTECH CORP.
    Inventors: Chin-Chung Lin, Jong-Tar Kuo, Ching-Chun Chen, Jent-turn Lee, Yu-Yen Lin
  • Patent number: 9198896
    Abstract: A pharmaceutical composition and treatment method to reduce the proliferation of cancerous or tumor cells, in which the combined active agents are methylglyoxal, ascorbic acid, creatine and melatonin.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: December 1, 2015
    Assignee: NATIONAL RESEARCH DEVELOPMENT CORPORATION
    Inventor: Manju Ray
  • Patent number: 9067884
    Abstract: The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 30, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20150147396
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Parimala Nacharaju, Chaim Tuckman-Vernon, Adam J. Friedman, Pedro Cabrales, Joel M. Friedman
  • Publication number: 20150147309
    Abstract: The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Inventors: Giancarlo Parenti, Caterina Porto, Marco Moracci, Maria Carmina Ferrara, Beatrice Cobucci-Ponzano, Generoso Andria
  • Publication number: 20150148360
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 28, 2015
    Inventors: Jung-Hsin Lin, Jim-Min Fang, Ting-Rong Chen, Jhih-Bin Chen, Ching-Chow Chen, Tzu-Tang Wei
  • Publication number: 20150148335
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • Patent number: 9040575
    Abstract: The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: May 26, 2015
    Assignee: PROFESSIONAL DIETETICS, S.R.L.
    Inventors: Franco Conti, Francesco Saverio Dioguardi
  • Patent number: 9034913
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: May 19, 2015
    Assignee: Pfizer Inc.
    Inventors: Renuka D. Reddy, Evgenyi Shalaev, Ravi M. Shanker, Carl B. Ziegler
  • Patent number: 9029406
    Abstract: The present application relates to new derivatives, substituted on the N terminus by a carboxyalkyl group, of monomethylauristatin E and monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and to the use of these derivatives for producing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments may be applied as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: May 12, 2015
    Assignee: Seattle Genetics, Inc
    Inventors: Hans-Georg Lerchen, Sherif El Sheikh, Beatrix Stelte-Ludwig, Joachim Schuhmacher, Mark Gnoth
  • Publication number: 20150126575
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20150126486
    Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi NAGANAWA, Kensuke KUSUMI, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Akito KAKUUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Shigeyuki NONAKA
  • Publication number: 20150119414
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
  • Patent number: 9018237
    Abstract: The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: April 28, 2015
    Inventor: Darlene E. McCord
  • Patent number: 9018206
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 28, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • Publication number: 20150111749
    Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Inventors: Huazhang Huang, Ratnakar Asolkar
  • Patent number: 9012454
    Abstract: This document provides methods and materials related to treating mammals (e.g., humans) having a sexual dysfunction that is refractory to treatment with a PDE V inhibitor. For example, methods and materials related to the use of an ACE inhibitor and/or an angiotensin II receptor blocker with a PDE V inhibitor to treat mammals having a sexual dysfunction (e.g., erective dysfunction) that is unresponsive to treatment with a PDE V inhibitor are provided.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: April 21, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Frank V. Brozovich